



December 9, 2021

Kidswell Bio Corporation

Code: 4584 (TSE Mothers)

Masaharu Tani, President & CEO

Announcement of the launch of Ranibizumab BS

Tokyo, December 9, 2021 – Kidswell Bio Corporation (“KWB”) has been collaborating with Senju Pharmaceutical Co., Ltd. based on the joint development agreement for the biosimilar in the ophthalmic area (Project name: GBS-007) executed on May 12, 2016, and Senju Pharmaceutical Co., Ltd. has started launching Ranibizumab biosimilar (gene-recombination) on December 9, 2021. This product is the first biosimilar of an ophthalmic VEGF inhibitor and is expected to become a new treatment option for retinal diseases and to contribute to reducing the economic burden on patients.

〈Reference〉

Press release from Senju Pharmaceutical Co., Ltd.

Ophthalmic VEGF Inhibitor

Launch of a New Treatment for “Ranibizumab BS Intravitreal Injection Kit 10 mg/mL ‘Senju’”

URL: <https://www.senju.co.jp/english/>

About Kidswell Bio Corporation (KWB)

Kidswell Bio Corporation will challenge pediatric disease as a new field, in addition to intractable and rare diseases on which GTS has also been focusing for R&D. We would like to contribute to children who have hopes and dreams for their bright future. Furthermore, with our biotech expertise and children’s potential vital force such as SHED and CSC, we envision creating new pharmaceuticals and therapeutics for all people under “Kids Well, All Well.”

Contact:

Kidswell Bio Corporation

Tel: +81-3-6222-9547 Mail: info@kidswellbio.com